We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
AAZZUR is a fintechs company founded on a strong desire to make banking intelligent, individual and interconnected. It is reinventing the way banks are built, and its data can be used to increase monetization, satisfaction and retention. This company was founded 18 months ago, but in the last month, it was contacted by fintechs, banks and one insurance company to help them with their problems. AAZZUR provides tools for common functions for the banking space. Its entrepreneurial team has a depth of experience, and the company has been to one of the world-leading accelerators, techstars. Now, it is looking to work together with banks, and its team has developed a neo-bank offering in record time that they are going to be soft-launched soon.
days to go: Expired investment: £400,991
B-North is a financial technology bank combining cloud-native technology with face-to-face relationship banking to disrupt the £150 billion UK Small and Medium Enterprise (SME) lending market. It argues that it delivers cash to SMEs faster than the competition by combining its lending origination platform with a locally delivered servicing and relationship model overseen by experienced bankers. B-North asserts that it is engaging in a positive dialogue with several potential investors with a committed investment now standing at £18.6 million since June 2020. The company has also raised a seed capital of over £6.8 million that includes a six-figure investment from the Greater Manchester Combined Authority to establish its core team and create both the lending and deposit-taking platforms. The company will use the investment to provide a cash runway to the end of Q2 2021 as the team finalises its Series A round and secures its banking license.
days to go: Expired investment: £883,835
A multi-award winning investment platform providing customers with ISA eligible loans. Crowdstacker are fully FCA regulated and set a record for the largest crowdfunded P2P loan in the UK, valued at £15m. With the recent release of Innovative Finance ISA, the company is expecting to see rapid growth in the near future.
days to go: Expired investment: £818,210
Nomisma is a cloud based platform that provide accounting capability for accountants and can be accessed from anywhere using any device. Nomisma was designed to reduce operating cocts by cutting down on softwares costs.  
days to go: Expired investment: £81,431
Vegums develop multivitamin gummies for a vegan and plant-based lifestyle. The company argues that some vitamins are difficult to get from a plant-only diet, such as vitamin D, B12, and iodine. Vegums has researched and incorporated non-animal vitamin ingredients into its products to address that issue. The company asserts that its products are 100% plastic-free and biodegradable. It claims that the number of vegans in the UK grew by 40% in 2020, and shows no sign of slowing down in 2021. It aims to become a contender in this segment. Vegums won the World Plant Award 2020 for the 'Best Plant-Based Start-Up', has a social media following of over 15,700 on Instagram, achieved 4.8/5 on TrustPilot, and scaled from selling 1 pack of Vegums to over 9,000 a month to its customers. It will use the investment for New Product Development (NPD), team expansion, and launching into new markets and countries.
days to go: Expired investment: £312,463
WeTRAIN is a new way to have fun with personal training. They are the first shared personal training company and by doing this, they are creating a market of social exercise. WeTRAIN makes it easy for friends to have high quality, personalised training in a variety of different classes.
days to go: Expired investment: £437,138
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph